Fatal Trichosporon fungemia in patients with hematologic malignancies

European Journal of Haematology

Volumn 84, Issue 5, 2010, Pages 441-447

  Suzuki, Kei ^a   Nakase, Kazunori ^a,b   Kyo, Taiichi ^c   Kohara, Tadahiro ^c   Sugawara, Yumiko ^a   Shibazaki, Tetsunori ^a   Oka, Kouji ^d   Tsukada, Tetsuya ^e   Katayama, Naoyuki ^a  

^a MIE UNIVERSITY   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d Suzuka Kaisei Hospital   (Japan)

^e Takeuchi Hospital   (Japan)

Author keywords

Acute leukemia; Breakthrough infection; Neutropenia; Trichosporon fungemia

Indexed keywords

AMPHOTERICIN B; BETA GLUCAN; FLUCONAZOLE; FOSFLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CANCER CHEMOTHERAPY; CATHETER REMOVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED TRICHOSPORONOSIS; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; INFECTION PREVENTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; TRICHOSPORON; YOUNG ADULT;

EID: 77951055000     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01410.x     Document Type: Article

References (31)

1. Haupt HM, Merz WG, Beschoner WE, Vaughan WP, Seral R. Colonization and infection with Trichosporon species in the immunocompromised host. J Infect Dis 1983 147 : 199 203.
2. Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989 3 : 43 52.
3. Hoy J, Hsu K-C, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev Infect Dis 1986 8 : 959 967.
4. Shimazu K, Ando M, Sakata T, Yoshida K, Araki S. Hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 1984 130 : 407 411.
5. Kataoka-Nishimura S, Akiyama H, Saku K, Kashiwa M, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Invasive infection due to Trichosporon cutaneum in patients with hematologic malignancies. Cancer 1998 82 : 484 487.
6. Krcmery V, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, Trupl J. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole. Support Care Cancer 1999 7 : 39 43.
7. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004 36 : 564 569.
8. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005 43 : 1818 1828.
9. Tokimatsu I, Kadota J. Emerging deep-seated fungal infection, Trichosporonosis. J Jpn Assoc Infect Dis 2006 80 : 196 202. (in Japanese).
10. National Committee for Clinical Laboratory Standards. Reference Method for broth Dilution Antifungal Susceptibility Testing of Yeast: Approved Standard. NCCLS document M27-A.
11. Nagai H, Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis. J Clin Microbiol 1999 37 : 694 699.
12. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker or in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002 87 : 978 982.
13. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003 78 : 1471 1478.
14. Leonidou L, Mouzaki A, Michalaki M, DeLastic AL, Kyriazopoulou V, Bassaris HP, Gogos CA. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect 2007 55 : 340 346.
15. Vasta S, Menozzi M, Scime R, Indovina A, Speciale A, Liberti G, Spano C, Majolino I. Central catheter infection by Trichosporon beigelii after autologous blood stem cell transplantation. a case report and review of the literature. Haematologica 1993 78 : 64 7.
16. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000 44 : 57 62.
17. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008 36 : 68 70.
18. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2004 42 : 753 757.
19. van Burik JH, Ratanatharathorn V, Stephen DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 39 : 1407 1416.
20. Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006 45 : 259 264.
21. Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2006 46 : 3 9.
22. Hashino S, Morita L, Takahata M, et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008 87 : 91 7.
23. Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008 88 : 588 595.
24. Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2007 26 : 843 845.
25. Erer B, Galimberti M, Lucarelli G, Giardini C, Polchi P, Baronciani D, Gaziev D, Angelucci E, Izzi G. Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts. Bone Marrow Transplant 2000 25 : 745 749.
26. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, Lee J, Callender D, Rubin M, Pizzo PA. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990 28 : 1616 1622.
27. Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, Sobel J, Bodey G. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992 15 : 781 787.
28. Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, Dombret H, Molina JM. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 2002 21 : 892 896.
29. Falk R, Wolf DG, Shaprio M, Polacheck I. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 2003 41 : 911.
30. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 1986 65 : 268 279.
31. Ofran Y, Avivi I, Oliven A, Oren I, Zuckerman T, Bonstein L, Rowe JM, Dann EJ. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang 2007 93 : 363 369.